EUCTR2007-005057-36-GB进行中（未招募）不适用
Evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic HIV-infected patients (HCQ-01) - Hydroxychloroquine study
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Documented HIV infection on ELISA and confirmatory test
- •2. Age 18 to 60 years
- •3. Naïve to antiretroviral therapy or off ART for at least 12 months prior to study entry
- •4. CD4 T-cell count greater than 400 cells/µL on screening blood test and on
- •one other test performed within 6 months prior to screening.
- •5. Plasma HIV RNA viral load greater than 1000 copies/ml on screening blood
- •6. Willing and able to provide written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of psoriasis, porphyria cutanea tarda, epilepsy, myasthenia gravis, myopathy of any cause, cardiac arrhythmias, glucose 6-phosphate dehydrogenase (G6PD) deficiency.
- •2. Insulin-dependent or non-insulin-dependent diabetes mellitus.
- •3. Chronic liver disease of any cause or alcoholism
- •4. Primary HIV infection within 12 months prior to screening, either confirmed (previous negative HIV antibody test within 12 months), or suspected (symptoms strongly suggestive of HIV seroconversion illness within the previous 12 months and patient not known to be HIV antibody positive prior to the illness)
- •5. Pneumonia, meningitis, septicaemia or any other serious infection in the 2 months prior to screening
- •6. Any acute infection with fever and systemic symptoms within the last 24 hours
- •7. Any vaccinations in the 2 months prior to screening
- •8. Active malignancy (patients are eligible if treatment for the malignancy was completed more than 2 years prior to screening and there has been no subsequent clinical evidence of active disease) or any active immune-mediated or inflammatory disease
- •9. Any known suicide attempts (at any time in the past) or current or past history of depression requiring treatment within the 2 years prior to screening. Patients who have not had depression in the previous 2 years but who have had depression in the past may be included if, in the opinion of the physician, the nature of the past episode of depression and the patient’s current psychological state indicate that the risk of recurrence of depression during the trial is likely to be low. Patients who have received anti-depressant medication for reasons other than symptomatic depression can be included in the trial.
- •10. A woman who is currently pregnant or breastfeeding
- •11. A woman of child-bearing potential who is planning to become pregnant during the course of the study, or is unwilling to take adequate contraception (including barrier contraception) throughout the course of the study.
- •12. Use of systemic corticosteroids or other immunomodulatory drugs within the 12 months prior to screening
- •13. Current use of medication with known serious hepatotoxic effects or known interaction with hydroxychloroquine.
- •14. Evidence of cardiac conduction defects or cardiac arrhythmia on screening ECG
- •15. Retinopathy or visual field changes detected on screening eye examination
- •16. Hepatitis B surface antigen (HBsAg) positive or Hepatitis C PCR positive (patients who are Hepatitis C antibody positive are allowed to participate provided that PCR is negative).
- •17. Any of the following laboratory abnormalities on screening blood test:
- •- Haemoglobin less than 10.5g/dl,
- •- Absolute neutrophil count less than 1.0x109/L
- •- Platelet count less than 100 X 109/L
- •- ALT or AST, or alkaline phosphatase above 2.5 x upper limit of normal (ULN)
- •- Serum creatinine greater than 1.5xULN
- •- Estimated creatinine clearance (Cockroft-Gault equation*) below 60ml/min
- •18. Inability to attend or comply with treatment or follow-up scheduling
- •19. Current participation in any other clinical intervention trial.
研究者
相似试验
已完成
不适用
HCQ-01 Trial: evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic human immunodeficiency virus (HIV) infected patientsISRCTN30019040Medical Research Council Clinical Trials Unit (MRC CTU) (UK)90
尚未招募
3 期
Efficacy of hydroxychloroquine in graves disease in addition to antithyroid drugs.CTRI/2023/07/054894IPQA laboratories
招募中
不适用
Evaluate the efficacy of hydroxychloroquine in the prevention of SARS-COV2 infection in high risk health care workersIRCT20200414047076N1Esfahan University of Medical Sciences160
招募中
3 期
Hydroxychloroquine in comparison with hydroxychloroquine + azithromycin in patients with covid-19COVID-19.U07.1 - COVID-19COVID-19IRCT20200428047228N2Quality Improvement of Intensive Care Research Center- Shahid Beheshti University40
进行中（未招募）
不适用
Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - NDHIV infection (immunological nonresponders).MedDRA version: 9.1Level: LLTClassification code 10008922EUCTR2009-012499-28-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)40